{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T15:52:01Z","timestamp":1648569121759},"reference-count":112,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.rmr.2011.08.005","type":"journal-article","created":{"date-parts":[[2011,11,7]],"date-time":"2011-11-07T18:43:19Z","timestamp":1320691399000},"page":"1340-1356","source":"Crossref","is-referenced-by-count":0,"title":["Prise en charge th\u00e9rapeutique de l\u2019atteinte des voies a\u00e9riennes distales dans la BPCO"],"prefix":"10.1016","volume":"28","author":[{"given":"P.","family":"Devillier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Jebrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Chinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Didier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2011.08.005_bib0005","unstructured":"National Heart Lung and Blood Institute. NIH, World Health Organization. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease; 2009. http:\/\/www.goldcopd.com. Dernier acc\u00e8s le 08\/04\/2011."},{"key":"10.1016\/j.rmr.2011.08.005_bib0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","article-title":"Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study","volume":"178","author":"Celli","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0020","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa041892","article-title":"Decreased histone deacetylase activity in chronic obstructive pulmonary disease","volume":"352","author":"Ito","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.rmr.2011.01.001","article-title":"Une nouvelle s\u00e9rie sur l\u2019atteinte des voies a\u00e9riennes distales dans la BPCO","volume":"28","author":"Dusser","year":"2011","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2011.08.005_bib0030","unstructured":"Garcia G, Perez T, Verbanck S. Explorations fonctionnelles respiratoires des voies a\u00e9riennes distales dans la BPCO. Rev Mal Respir. In press."},{"key":"10.1016\/j.rmr.2011.08.005_bib0035","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.rmr.2011.01.009","article-title":"Modifications structurales et inflammation dans la BPCO\u00a0importance des voies a\u00e9riennes distales","volume":"28","author":"Burgel","year":"2011","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2011.08.005_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0761-8425(09)73539-9","article-title":"Pourquoi et comment mesurer et optimiser le d\u00e9p\u00f4t pulmonaire des traitements inhal\u00e9s\u00a0?","volume":"26","author":"Devillier","year":"2009","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2011.08.005_bib0045","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMoa032158","article-title":"The nature of small-airway obstruction in chronic obstructive pulmonary disease","volume":"350","author":"Hogg","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0050","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.120.1.258","article-title":"Alternative mechanisms for \u03b22-long-acting adrenergic agonist in COPD","volume":"120","author":"Johnson","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/pupt.1997.0082","article-title":"Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils","volume":"10","author":"Leff","year":"1997","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rmr.2011.08.005_bib0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.98.12040799","article-title":"Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients","volume":"12","author":"Tantucci","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2011.08.005_bib0065","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1378\/chest.122.6.2009","article-title":"Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD","volume":"122","author":"Duranti","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0070","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2125.2007.03013.x","article-title":"The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD","volume":"65","author":"Borrill","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rmr.2011.08.005_bib0075","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/ajrccm\/146.1.88","article-title":"Effective site of bronchodilation by beta-adrenergic and anticholinergic agents in patients with chronic obstructive pulmonary disease: direct measurement of intrabronchial pressure with new catheter","volume":"146","author":"Ohrui","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmr.2011.08.005_bib0080","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/bjp.2008.185","article-title":"Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans","volume":"154","author":"Wessler","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.rmr.2011.08.005_bib0085","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1378\/chest.124.5.1743","article-title":"Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes","volume":"124","author":"Celli","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0090","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1183\/09031936.04.00116004","article-title":"Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD","volume":"23","author":"O\u2019Donnell","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2011.08.005_bib0095","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1159\/000089655","article-title":"The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease","volume":"73","author":"Verkindre","year":"2006","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2011.08.005_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/COPD.S2386","article-title":"Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium","volume":"3","author":"Incorvaia","year":"2008","journal-title":"Int J COPD"},{"key":"10.1016\/j.rmr.2011.08.005_bib0105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/09031936.00023907","article-title":"Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD","volume":"30","author":"Powrie","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2011.08.005_bib0110","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1183\/09031936.00115308","article-title":"Anti-inflammatory effects of salmeterol\/fluticasone, tiotropium\/fluticasone or tiotropium in COPD","volume":"33","author":"Perng","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2011.08.005_bib0115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1440-1681.1978.tb00707.x","article-title":"Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline","volume":"5","author":"Poolson","year":"1978","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.rmr.2011.08.005_bib0120","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1164\/rccm.2105106","article-title":"Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease","volume":"165","author":"Culpitt","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0125","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/bmj.297.6662.1506","article-title":"Dose response relation to oral theophylline in severe chronic obstructive airways disease","volume":"297","author":"Chrystyn","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.rmr.2011.08.005_bib0130","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1378\/chest.101.1.166","article-title":"A comparison of the effects of anticholinergic and \u03b2\u2013agonist and combination therapy on impedance in COPD","volume":"101","author":"Wesseling","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0135","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.rmed.2004.05.003","article-title":"The functional impact of adding salmeterol and tiotropium in patients with stable COPD","volume":"98","author":"Cazzola","year":"2004","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0140","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1378\/chest.129.3.509","article-title":"Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD","volume":"129","author":"Van Noord","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0145","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/thx.2007.087213","article-title":"Superiority of \u201ctriple\u201d therapy with salmeterol\/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD","volume":"63","author":"Singh","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2011.08.005_bib0150","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1378\/chest.105.4.1089","article-title":"A comparison of inhaled ipratropium, oral theophylline plus inhaled \u03b2\u2013agonist and the combination of all three in patients with COPD","volume":"105","author":"Karpel","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0155","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1378\/chest.119.6.1661","article-title":"Salmeterol plus theophylline combination therapy in the treatment of COPD","volume":"119","author":"ZuWallack","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1165\/rcmb.2002-0121OC","article-title":"Mechanical stress triggers selective release of fibrotic mediators from bronchial epithelium","volume":"28","author":"Tschumperlin","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.rmr.2011.08.005_bib0165","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1378\/chest.117.6.1633","article-title":"Inhaled corticosteroids in stable COPD patients","volume":"117","author":"Balbi","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0170","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.rmed.2005.04.025","article-title":"The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8\u00a0levels in stable COPD patients","volume":"99","author":"Ozol","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0175","first-page":"109","article-title":"Effect of an inhaled glucorticoid on reactive oxygen species production by bronchoalveolar lavage cells from smoking COPD patients","volume":"9","author":"Verhoeven","year":"2000","journal-title":"Inflammation"},{"key":"10.1016\/j.rmr.2011.08.005_bib0180","unstructured":"Williamson P, Menzies D, Clearie K, et al. Dose-response for inhaled fluticasone on airway and systemic inflammation in COPD. Congress of the European Respiratory Society 2009:A2015."},{"key":"10.1016\/j.rmr.2011.08.005_bib0185","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/rmed.2001.1124","article-title":"Effects of diffusing capacity and ventilation-perfusion relationships of budesonide inhalations for 2\u00a0months in chronic obstructive pulmonary disease","volume":"95","author":"Sandek","year":"2001","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0190","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1378\/chest.118.4.990","article-title":"Controlled short-term trial of fluticasone propionate in ventilator-dependent patients with COPD","volume":"118","author":"Nava","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000119718","article-title":"Inhaled corticosteroids as additional treatment in alpha1-antitrypsin-deficiency-related COPD","volume":"76","author":"Corda","year":"2008","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2011.08.005_bib0200","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1378\/chest.130.3.647","article-title":"Effect of fluticasone propionate\/salmeterol on lung hyperinflation and exercise endurance in COPD","volume":"130","author":"O\u2019Donnell","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0205","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jaci.2008.07.040","article-title":"Steroids completely reverse albuterol-induced b2-adrenergic receptor tolerance in human small airways","volume":"122","author":"Cooper","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2011.08.005_bib0210","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2125.2007.02856.x","article-title":"Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction","volume":"64","author":"Mortimer","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rmr.2011.08.005_bib0215","first-page":"169","article-title":"Survival in idiopathic pulmonary fibrosis: results of the IFIGENIA follow-up study","author":"Thomeer","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0220","doi-asserted-by":"crossref","unstructured":"Chapron-Fouch\u00e9 J, Burgel PR. Mucolytiques et th\u00e9rapeutiques augmentant la clairance mucociliaire. EMC (Elsevier Masson SAS Paris) Pneumologie, 6000\u00a0P-10, 2009.","DOI":"10.1016\/S1155-195X(09)47939-8"},{"key":"10.1016\/j.rmr.2011.08.005_bib0225","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1164\/ajrccm.156.2.9611013","article-title":"Oxydative stress in chronic obstructive pulmonary disease","volume":"156","author":"Repine","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0230","first-page":"1067","article-title":"Lung glutathione and oxydative stress: implications in cigarette smoke-induced airway disease","volume":"277","author":"Rahman","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.rmr.2011.08.005_bib0235","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM200007273430407","article-title":"Chronic obstructive pulmonary disease","volume":"343","author":"Barnes","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0240","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1183\/09031936.04.00016804","article-title":"Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease","volume":"23","author":"Dekhuijzen PN","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2011.08.005_bib0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000195086","article-title":"Lung protection by a thiol-containing antioxydant N-acetylcysteine","volume":"50","author":"Moldeus","year":"1986","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2011.08.005_bib0250","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1517\/14656560902758343","article-title":"Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases","volume":"10","author":"Maccio","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.rmr.2011.08.005_bib0255","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-utility Study, BRONCUS): a randomised placebo-controlled trial","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2011.08.005_bib0260","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","article-title":"Effect of carbocistein on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study","volume":"371","author":"Zheng","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2011.08.005_bib0265","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1378\/chest.09-0421","article-title":"Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo controlled study","volume":"136","author":"Stav","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0270","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pupt.2004.10.005","article-title":"Prediction of treatment-response to inhaled corticosteroids by mannitol challenge test in COPD. A proof of concept","volume":"18","author":"Leuppi","year":"2005","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rmr.2011.08.005_bib0275","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1183\/09031936.96.09040769","article-title":"Effect on rh Dnase on purulent airway secretions in chronic bronchitis","volume":"9","author":"Puchelle","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2011.08.005_bib0280","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00210-008-0293-8","article-title":"Pulmonary pharmacokinetics and safety and nebulized duramycin in healthy male volunteers","volume":"378","author":"Steiner","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.rmr.2011.08.005_bib0285","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1378\/chest.121.5_suppl.201S","article-title":"P2Y2\u00a0receptor agonists","volume":"121","author":"Kellerman","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0290","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1183\/09031936.96.09040725","article-title":"Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects","volume":"9","author":"Daviskas","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2011.08.005_bib0295","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1183\/09031936.01.17201950","article-title":"Hypertonic saline alters ion transport across the human airway epithelium","volume":"17","author":"Middleton","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2011.08.005_bib0300","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1164\/ajrccm.164.10.2104024","article-title":"Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease","volume":"164","author":"Taube","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0305","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1056\/NEJMra0800353","article-title":"Infection in the pathogenesis and course of chronic obstructive pulmonary disease","volume":"359","author":"Sethi","year":"2008","journal-title":"N Eng J Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0310","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1513\/pats.200701-003FM","article-title":"Exacerbations of chronic obstructive pulmonary disease","volume":"4","author":"Anzueto","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmr.2011.08.005_bib0315","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/COPD.S1089","article-title":"Optimizing antibiotic selection in treating COPD exacerbations","volume":"3","author":"Siddiqi","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2011.08.005_bib0320","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1183\/09031936.01.17509950","article-title":"Bacteria, antibiotics and COPD","volume":"17","author":"Wilson","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2011.08.005_bib0325","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1513\/pats.200905-025DS","article-title":"New paradigms in the pathogenesis of chronic obstructive pulmonary disease II","volume":"6","author":"Sethi","year":"2009","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmr.2011.08.005_bib0330","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2011.08.005_bib0335","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1164\/rccm.200305-648OC","article-title":"Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease","volume":"170","author":"Patel","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0340","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial","volume":"61","author":"Cl\u00e9ment","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2011.08.005_bib0345","first-page":"CD002203","article-title":"Macrolide antibiotics for cystic fibrosis","volume":"2","author":"Southern","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2011.08.005_bib0350","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.rmed.2004.06.009","article-title":"The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD","volume":"99","author":"Banerjee","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0355","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","article-title":"Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations","volume":"178","author":"Seemungal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0360","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/COPD.S681","article-title":"Role of macrolide therapy in chronic obstructive pulmonary disease","volume":"3","author":"Martinez","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2011.08.005_bib0365","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1164\/rccm.200711-1666OC","article-title":"Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease","volume":"178","author":"Hodge","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0370","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjp.2008.307","article-title":"PDE4\u00a0inhibitors: current status","volume":"155","author":"Spina","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.rmr.2011.08.005_bib0375","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(05)67100-0","article-title":"Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial","volume":"366","author":"Rabe","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2011.08.005_bib0380","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/0003495-200868002-00002","article-title":"The efficacy and safety of cilomilast in COPD","volume":"68","author":"Rennard","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.rmr.2011.08.005_bib0385","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1586\/ers.10.56","article-title":"Roflumilast for the treatment of chronic obstructive pulmonary disease","volume":"4","author":"Rabe","year":"2010","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0390","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1378\/chest.09-0194","article-title":"Statins in COPD: a systematic review","volume":"136","author":"Janda","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0395","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/thx.2003.018879","article-title":"Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium","volume":"59","author":"Burgel","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2011.08.005_bib0400","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1385\/CBB:47:1:131","article-title":"Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy","volume":"47","author":"de Boer","year":"2007","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.rmr.2011.08.005_bib0405","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1378\/chest.08-1385","article-title":"Emerging pharmacotherapies for COPD","volume":"134","author":"Barnes","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0410","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1172\/JCI36130","article-title":"The cytokine network in asthma and chronic obstructive pulmonary disease","volume":"118","author":"Barnes","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0415","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pupt.2007.03.003","article-title":"TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease","volume":"21","author":"Suissa","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rmr.2011.08.005_bib0420","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"COPD Investigators. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0425","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000117386","article-title":"Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study","volume":"76","author":"Dentener","year":"2008","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2011.08.005_bib0430","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/187152807780832292","article-title":"CC-chemokine receptors in chronic obstructive pulmonary disease","volume":"6","author":"Bracke","year":"2007","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.rmr.2011.08.005_bib0435","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.pupt.2007.10.007","article-title":"Effect of the oral leukotriene B4\u00a0receptor antagonist LTB019\u00a0on inflammatory sputum markers in patients with chronic obstructive pulmonary disease","volume":"21","author":"Gr\u00f6nke","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rmr.2011.08.005_bib0440","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00063030-200822020-00002","article-title":"Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease","volume":"22","author":"Woodside","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.rmr.2011.08.005_bib0445","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2008.09.008","article-title":"Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies","volume":"121","author":"Djekic","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.rmr.2011.08.005_bib0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2008.09.003","article-title":"Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease","volume":"121","author":"Edwards","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.rmr.2011.08.005_bib0455","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/COPD.S7390","article-title":"Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease","volume":"5","author":"Marwick","year":"2010","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2011.08.005_bib0460","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1183\/09031936.04.00039004","article-title":"Asthma and cigarette smoking","volume":"24","author":"Thomson","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2011.08.005_bib0465","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1378\/chest.08-0440","article-title":"Molecular mechanisms of corticosteroid resistance","volume":"134","author":"Adcock","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0470","doi-asserted-by":"crossref","first-page":"235S","DOI":"10.1378\/chest.117.5_suppl_1.235S","article-title":"Effects of all-trans-retinoic acid in promoting alveolar repair","volume":"117","author":"Belloni","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0475","first-page":"1243","article-title":"Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema","volume":"10","author":"Hind","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.rmr.2011.08.005_bib0480","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/1753465810379617","article-title":"Retinoid treatment of emphysema in patients on the Alpha-1\u00a0International Registry. The REPAIR study: study design, methodology and quality control of study assessments","volume":"4","author":"Stolk","year":"2010","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.rmr.2011.08.005_bib0485","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1517\/14712591003610614","article-title":"Mesenchymal stem cell therapy for the treatment of chronic obstructive pulmonary disease","volume":"10","author":"D\u2019Agostino","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.rmr.2011.08.005_bib0490","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.rmed.2006.01.008","article-title":"The need to improve inhalation technique in Europe: a report from the aerosol drug management improvement team","volume":"100","author":"Crompton","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0495","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.rmed.2007.07.031","article-title":"Importance of inhaler devices in the management of airway disease","volume":"102","author":"Virchow","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0500","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1378\/chest.127.1.335","article-title":"Device selection and outcomes of aerosol therapy: evidence based guidelines","volume":"127","author":"Dolovich","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.08.005_bib0505","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.pupt.2006.05.005","article-title":"Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology","volume":"20","author":"Acerbi","year":"2007","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rmr.2011.08.005_bib0510","first-page":"251","article-title":"Use of respimat soft mist inhaler in COPD patients","volume":"1","author":"Anderson","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2011.08.005_bib0515","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2147\/COPD.S3930","article-title":"Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique","volume":"3","author":"Brand","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2011.08.005_bib0520","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/med.20140","article-title":"Nanoparticle formulations in pulmonary drug delivery","volume":"29","author":"Bailey","year":"2009","journal-title":"Med Res Rev"},{"key":"10.1016\/j.rmr.2011.08.005_bib0525","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.bioeng.10.061807.160544","article-title":"Targeted drug-aerosol delivery in the human respiratory system","volume":"10","author":"Kleinstreuer","year":"2008","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.rmr.2011.08.005_bib0530","first-page":"1304","article-title":"Dry powder inhalers: an overview","volume":"50","author":"Atkins","year":"2005","journal-title":"Respir Care"},{"key":"10.1016\/j.rmr.2011.08.005_bib0535","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0954-6111(97)90009-3","article-title":"Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler","volume":"91","author":"Everard","year":"1997","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0540","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1164\/rccm.200410-1414OC","article-title":"Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size","volume":"172","author":"Usmani","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2011.08.005_bib0545","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1089\/dia.2005.7.896","article-title":"EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin","volume":"7","author":"White","year":"2005","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.rmr.2011.08.005_bib0550","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/03639040802144211","article-title":"Current therapies and technological advances in aqueous aerosol drug delivery","volume":"34","author":"Watts","year":"2008","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.rmr.2011.08.005_bib0555","first-page":"504","article-title":"La n\u00e9bulisation en pratique chez l\u2019enfant","volume":"47","author":"Juchet","year":"2007","journal-title":"Rev Fr Allergol Immunol Clin"},{"key":"10.1016\/j.rmr.2011.08.005_bib0560","first-page":"615","article-title":"Novel approaches to enhance pulmonary delivery of proteins and peptides","volume":"58","author":"Scheuch","year":"2007","journal-title":"J Physiol Pharmacol"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842511003895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842511003895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T05:30:06Z","timestamp":1560922206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842511003895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":112,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0761842511003895"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2011.08.005","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}